IntelGenx Provides Update on Research Collaboration Evaluating Montelukast VersaFilm® for the Treatment of Parkinson’s Disease

Published on July 25, 2023

7/25/2023

IntelGenx Corp. today announced the execution of a Research Grant Agreement with Karolinska University Hospital and that the manufacturing of both active and placebo films are underway in preparation for a planned multicentre, randomized, double-blind, placebo-controlled clinical study (the “Study”) to investigate the use of IntelGenx’s Montelukast VersaFilm ® for the treatment of Parkinsons Disease.

 


(Feed generated with FetchRSS)

 

Continue reading on website
Other news

AbCellera Announces that the U.S. Patent Trial and Appeal Board Has Denied Berkeley Lights’ Request for Rehearing

July 24, 2023
VANCOUVER, BC — (BUSINESS WIRE) — AbCellera (Nasdaq: ABCL) announced that the United States Patent and Trademark Office’s (USPTO) Patent Trial and Appeal Board (PTAB) has denied a rehearing request in an Inter Partes Review (IPR) filed by Berkeley Lights, Inc. (Berkeley Lights) that challenged AbCellera’s U.S. Patent No. 10,087,408 (the ‘408 Patent). AbCellera’s ‘408 Patent is directed to microflu

Humanigen mulls bankruptcy after reverse merger falls through

July 25, 2023
Humanigen mulls bankruptcy after reverse merger falls through ntaylor Tue, 07/25/2023 - 07:21Humanigen is running out of options. Talks over a reverse merger have collapsed and, with efforts to find another deal or raise funding failing, the biotech is considering filing for bankruptcy in the third quarter. The New Jersey-based biotech has been on the ropes since its anti-human GM-CSF monoclonal a